This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

G1 Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

G1 Therapeutics şirketinin toplam hissedar öz sermayesi $24.6M ve toplam borcu $44.3M olup, bu da borç-öz sermaye oranını 180.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $98.7M ve $74.1M dir.

Anahtar bilgiler

180.2%

Borç/özkaynak oranı

US$44.32m

Borç

Faiz karşılama oranı	n/a
Nakit	US$60.73m
Eşitlik	US$24.59m
Toplam yükümlülükler	US$74.10m
Toplam varlıklar	US$98.69m

Son finansal sağlık güncellemeleri

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

Recent updates

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

Jul 26

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Jun 24

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Jun 07

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

May 28

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 04

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Mar 22

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

Feb 27

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Feb 06

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Jan 04

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

Jun 08

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

May 08

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Nov 04

G1 Therapeutics: Catalysts Stacking

Oct 20

G1 Therapeutics: Building A Franchise

Sep 29

Analysts Just Published A Bright New Outlook For G1 Therapeutics, Inc.'s (NASDAQ:GTHX)

Aug 04

G1 Therapeutics Q2 2022 Earnings Preview

Aug 02

G1 Therapeutics: Take Advantage Of The November Data

Jul 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: GTHX 'nin kısa vadeli varlıkları ( $92.9M ) kısa vadeli yükümlülüklerini ( $37.5M ) aşıyor.

Uzun Vadeli Yükümlülükler: GTHX şirketinin kısa vadeli varlıkları ( $92.9M ) uzun vadeli yükümlülüklerini ( $36.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: GTHX şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: GTHX şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 180.2% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: GTHX şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: GTHX tarihsel oranlara göre serbest nakit akışı büyümeye veya küçülmeye devam ederse yeterli nakit pistine sahip olup olmadığını belirlemek için yeterli veri yok.

Sağlıklı şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2024/09/18 15:06
Gün Sonu Hisse Fiyatı	2024/09/18 00:00
Kazançlar	2024/06/30
Yıllık Kazançlar	2023/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube'da eğitimlerimiz bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.

Analist Kaynakları

G1 Therapeutics, Inc. 8 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
Harshita Polishetty	B. Riley Securities, Inc.
Dane Leone	BTIG
Charles Butler	D. Boral Capital LLC.

This company has been acquired

G1 Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 4/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

Recent updates

G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index

New minor risk - Shareholder dilution

Consensus EPS estimates upgraded to US$0.39 loss

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.

New major risk - Share price stability

There's No Escaping G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Muted Revenues Despite A 80% Share Price Rise

G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Price target decreased by 10.0% to US$7.50

G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer

G1 Therapeutics: Failure Of Breast Cancer Underscores Long-Term Uncertainty

Shareholders May Not Be So Generous With G1 Therapeutics, Inc.'s (NASDAQ:GTHX) CEO Compensation And Here's Why

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting

CEO, President & Director recently sold US$178k worth of stock

Consensus estimates of losses per share improve by 18%

G1 Therapeutics, Inc. (NASDAQ:GTHX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

First quarter 2024 earnings: EPS in line with expectations, revenues disappoint

G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Why G1 Therapeutics Is A Speculative 'Buy' In The Oncology Biotech Landscape

Forecast breakeven date pushed back to 2026

Full year 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024

Consensus estimates of losses per share improve by 22%

Why Investors Shouldn't Be Surprised By G1 Therapeutics, Inc.'s (NASDAQ:GTHX) 44% Share Price Plunge

G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Chief Medical Officer notifies of intention to sell stock

Price target decreased by 12% to US$8.33

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Does G1 Therapeutics (NASDAQ:GTHX) Have A Healthy Balance Sheet?

G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC

CEO, President & Director recently sold US$108k worth of stock

G1 Therapeutics, Inc. (NASDAQ:GTHX) Stock Catapults 61% Though Its Price And Business Still Lag The Industry

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023

New minor risk - Share price stability

G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023

Consensus EPS estimates upgraded to US$0.96 loss

Price target decreased by 21% to US$8.80

New minor risk - Market cap size

New minor risk - Profitability

No longer forecast to breakeven

Consensus estimates of losses per share improve by 29%

G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

Little Excitement Around G1 Therapeutics, Inc.'s (NASDAQ:GTHX) Revenues

G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer

Forecast to breakeven in 2025

G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate

Consensus revenue estimates increase by 26%

New Forecasts: Here's What Analysts Think The Future Holds For G1 Therapeutics, Inc. (NASDAQ:GTHX)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023

Consensus EPS estimates upgraded to US$2.01 loss, revenue downgraded

Full year 2022 earnings: EPS exceeds analyst expectations

Consensus EPS estimates upgraded to US$2.19 loss, revenue downgraded

G1 Therapeutics, Inc. Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with Folfoxiri + Bevacizumab for Metastatic Colorectal Cancer (CRC) (Preserve 1)

Price target decreased by 45% to US$16.40

CEO, President & Director recently sold US$219k worth of stock

G1 Therapeutics, Inc. Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

CEO, President & Director notifies of intention to sell stock

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (Pfs) Data Expected in Mid-2023

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer

G1 Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.05 million.

Price target decreased to US$32.86

The G1 Therapeutics, Inc. (NASDAQ:GTHX) Analysts Have Been Trimming Their Sales Forecasts

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (Adc)